NAD+

II. What is this compound?

NAD+ exists in two forms: the oxidized NAD+ and the reduced NADH. Together, they form a redox pair essential for hundreds of enzymatic reactions. The molecule itself is a dinucleotide—two nucleotides joined through their phosphate groups—with a molecular weight of approximately 663 daltons [3] PMID: 32573651 .

Unlike peptides, NAD+ is not encoded by genes or assembled on ribosomes. It is synthesized endogenously through three distinct pathways: the salvage pathway (recycling nicotinamide via the enzyme NAMPT), the de novo pathway (building NAD+ from tryptophan through the kynurenine route), and the precursor pathway (consuming NMN or NR, which are converted to NAD+ inside cells) [4] PMID: 26785480 .

The salvage pathway handles the majority of NAD+ turnover in most tissues. NAMPT, the rate-limiting enzyme, has itself become a research target because its activity declines with age—potentially explaining why NAD+ pools shrink over time.

NAD+ cannot be taken directly as a supplement in meaningful amounts because it is rapidly degraded in the gut and bloodstream. Instead, research has focused on precursors—NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside)—that cells can absorb and convert into NAD+ through intracellular enzymatic steps [5] PMID: 27721479 .

III. How it works

The scientific interest in NAD+ centers on three enzyme families that consume it as a substrate—and whose activity depends directly on NAD+ availability.

Sirtuins (SIRT1–7) are NAD+-dependent protein deacetylases. They remove acetyl groups from histones and other proteins, altering gene expression and protein function. SIRT1 regulates metabolic homeostasis, fat storage, and glucose metabolism. SIRT3, SIRT4, and SIRT5 operate inside mitochondria, controlling oxidative stress and energy production. SIRT6 influences DNA repair and telomere maintenance. Research in yeast, worms, and mice has demonstrated that sirtuin activation can extend lifespan under certain conditions, though the translation to humans remains under investigation [6] PMID: 24786309 .

PARPs (poly(ADP-ribose) polymerases), particularly PARP-1 and PARP-2, use NAD+ to build poly(ADP-ribose) chains at sites of DNA damage. This molecular flag recruits repair machinery to single-strand breaks. Every repair event consumes NAD+; chronic DNA damage—as accumulates with age—can deplete cellular NAD+ pools substantially. Research suggests this PARP-mediated drain may compete with sirtuins for the same NAD+ pool, creating a functional trade-off between DNA repair and metabolic regulation [7] PMID: 31065944 .

CD38 is an NAD+-consuming glycohydrolase whose expression increases with age. Studies indicate CD38 may be the primary driver of age-related NAD+ decline in certain tissues, degrading both NAD+ and its precursor NMN. This has made CD38 inhibition an active area of pharmacological research [8] PMID: 26785480 .

The interplay between these three enzyme families creates what researchers describe as an NAD+ sink: as PARP and CD38 activity increase with age, sirtuin activity declines—not because sirtuins are damaged, but because their substrate is being consumed elsewhere [9] PMID: 32573651 .

• Substrate for sirtuin family (SIRT1–7) protein deacetylases regulating metabolic homeostasis, stress response, and mitochondrial function
  PMID 24786309PMID 26785480
• Substrate for PARP-1/PARP-2 poly(ADP-ribose) polymerases mediating DNA damage sensing and single-strand break repair
  PMID 31065944PMID 32573651
• Substrate for CD38/CD157 glycohydrolases; CD38 activity increases with age and depletes cellular NAD+ pools
  PMID 26785480PMID 32573651
• Cofactor in mitochondrial oxidative phosphorylation (Complex I, NADH dehydrogenase) linking NAD+/NADH ratio to cellular bioenergetics
  PMID 26785480

IV. Research Findings

Research on metabolic health has produced the most robust clinical data for NAD+ precursors. A randomized, double-blind trial administering 1000 mg/day of NR to obese adults for six weeks found increased skeletal muscle NAD+ metabolites and modest improvements in body composition and sleeping metabolic rate [10] PMID: 32320006 . A separate dose-response study showed NR at 300 mg/day raised whole-blood NAD+ by 48%, and at 1000 mg/day by 139%, over eight weeks in overweight adults [11] PMID: 29184669 .

Anti-aging and longevity research remains primarily preclinical. In aged mice, NMN supplementation restored NAD+ levels to those of younger animals and improved insulin sensitivity, mitochondrial function, and markers of inflammation [12] PMID: 24786309 . These findings have driven the hypothesis that replenishing NAD+ could slow or partially reverse certain biological aging processes.

DNA repair capacity is directly linked to NAD+ availability. Studies show that reduced intracellular NAD+ levels suppress recruitment of the DNA repair protein XRCC1 to sites of genomic damage. Supplementation with NAD+ or NMN restored repair capacity in cell culture models [13] PMID: 31065944 .

Cognitive function has emerged as a frontier for NAD+ research. Preclinical models suggest that brain NAD+ decline contributes to neurodegeneration, and early clinical trials are testing whether NR supplementation can improve cognition in Alzheimer's and Parkinson's disease patients [14] PMID: 31577933 .

A 2024 randomized trial of NMN in 80 middle-aged adults found significant increases in blood NAD+ at 30 and 60 days across all dose groups (300, 600, and 900 mg/day) compared to placebo, with improvements in physical performance on the six-minute walking test [15] PMID: 36482258 .

• anti-aging preclinical and early clinical
  PMID 24786309PMID 26785480
• metabolic-health clinical
  PMID 32320006PMID 36482258
• dna-repair preclinical
  PMID 31065944PMID 32573651
• cognitive-function preclinical and early clinical
  PMID 31577933

V. Dosage Context Explained

Published human dosing data derive from a growing body of randomized controlled trials, primarily using oral NR and NMN.

Nicotinamide riboside (NR) has been tested at 100–2000 mg/day. The most cited dose-response study found 300 mg/day effective for meaningful NAD+ elevation, with 1000 mg/day producing a 139% increase over eight weeks [16] PMID: 29184669 . A safety-focused trial in 120 adults aged 60–80 confirmed that NR combined with pterostilbene was well-tolerated, with NAD+ increases of 40% (standard dose) to 90% (double dose) after four weeks [17] PMID: 29184669 .

Nicotinamide mononucleotide (NMN) has been studied at 250–900 mg/day. A multicenter trial in 80 middle-aged adults demonstrated significant NAD+ elevation at all tested doses, with 900 mg/day showing the largest effect [18] PMID: 36482258 . Chronic supplementation at 250 mg/day for 12 weeks in healthy older men was safe and well-tolerated, significantly increasing blood NAD+ and related metabolites.

All dosing data come from research contexts. No regulatory agency has established approved dosing guidelines for NAD+ precursors in humans. The optimal dose, duration, and long-term safety profile remain active areas of investigation.

• Administration Routes

  oral (nicotinamide riboside)

  Range

  100–2000 mg/day

  randomized controlled trials in healthy adults; dose-dependent NAD+ elevation (100 mg = +10%, 300 mg = +48%, 1000 mg = +139% at 8 weeks)

  PMID 29184669PMID 32320006
• Administration Routes

  oral (NMN)

  Range

  250–900 mg/day

  placebo-controlled RCTs in middle-aged and older adults; significant blood NAD+ elevation at 30–60 days

  PMID 36482258

VI. Side Effects: Research Context

NAD+ precursors have demonstrated a favorable safety profile across published clinical trials. In studies administering NR at doses up to 2000 mg/day for 12 weeks, no serious adverse events were reported [19] PMID: 29184669 . Mild gastrointestinal discomfort has been noted anecdotally at higher doses.

Nicotinamide (the simplest NAD+ precursor) can cause flushing at high doses—a vasodilatory response mediated by prostaglandins. This effect is well-characterized and dose-dependent, but distinct from NR and NMN, which do not typically produce flushing.

Theoretical concerns center on tumor metabolism. Cancer cells often upregulate NAD+ biosynthesis to fuel rapid proliferation. While no clinical evidence links NAD+ precursor supplementation to accelerated tumor growth, the mechanistic plausibility warrants caution in individuals with active malignancies [20] PMID: 32573651 .

Long-term safety data beyond 12 weeks of continuous supplementation are limited. The absence of reported severe adverse events should not be interpreted as comprehensive safety evidence. Larger cohorts, longer durations, and post-marketing surveillance are needed.

• mild gastrointestinal discomfort at higher doses (anecdotal)
• flushing with nicotinamide at high doses
• no serious adverse events reported in clinical trials up to 2000 mg/day NR for 12 weeks

VII. Frequently Asked Questions